This section contains press releases and other materials from third parties (including paid content). The Globe and Mail has not reviewed this content. Please see disclaimer.
Goldman Sachs Sticks to Its Buy Rating for Astellas Pharma (ALPMF)
In a report released today, from Goldman Sachs maintained a Buy rating on Astellas Pharma, with a price target of Yen2,800.00.
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Currently, the analyst consensus on Astellas Pharma is a Hold with an average price target of Yen2,382.10.
ALPMF market cap is currently Yen4610.8B and has a P/E ratio of 9.34.
Read More on ALPMF:
Disclaimer & DisclosureReport an Issue
- Astellas’ Menopause Drug Fezolinetant Hits Key Safety Milestone in Japan
- Astellas Highlights R&D Strategy While Flagging Market and Development Risks
- Astellas and HOVON Phase 3 AML Trial for Xospata Misses Survival Goal
- Astellas Flags Risks and Uncertainties Around Sustainability Plans and Pipeline
- Why Is Vir Biotechnology Stock Up Today?
This article contains syndicated content. We have not reviewed, approved, or endorsed the content, and may receive compensation for placement of the content on this site. For more information please view the Barchart Disclosure Policy here.
